Abstract B47: CBP501, a novel cell cycle dysregulator, in combination with cisplatin (CDDP) and pemetrexed (PM) ‐ results of two phase I/II studies

TY - JOUR

T1 - Abstract B47: CBP501, a novel cell cycle dysregulator, in combination with cisplatin (CDDP) and pemetrexed (PM) ‐ results of two phase I/II studies

AU - Sharma, Sunil

AU - Tibes, Raoul

AU - Bastos, Bruno

AU - Borad, Mitesh

AU - Wong, Bryan

AU - Wasserman, Ernesto

AU - Fernandez, Cristian

AU - Kawabe, Takumi

AU - Von Hoff, Daniel

AU - Shapiro, Geoffrey I.

N1 - Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 15-19, 2009; Boston, MA Background: CBP501 is a synthetic peptide that appears to increase intracellular CDDP and enhance DNA damage caused by bleomycin and CDDP in cancer cells, which may lead to cell death. Activity has been identified in various tumor models.

PY - 2009/12/10

Y1 - 2009/12/10

UR - https://mct.aacrjournals.org/content/8/12_Supplement/B47

U2 - 10.1158/1535-7163.TARG-09-B47

DO - 10.1158/1535-7163.TARG-09-B47

M3 - Article

VL - 8

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

ER -